secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2023-02-06T23:59:59+00:00
Accession:  0000950170-23-001831
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Biomedical CMO/CVO Thomas Ciulla resigns effective Feb 17; will serve as advisor
--------------------------------------------------------------------------------

- Thomas Ciulla resigns as Chief Medical Officer and Chief Development Officer of Clearside Biomedical.
- Resignation effective February 17, 2023; he will continue as Chairman of Scientific Advisory Board.
- Ciulla will also serve as Chief Medical Advisor – Retina under a proposed consulting agreement.
- No successor named; Ciulla’s advisory role aims to maintain continuity in clinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017023001831/0000950170-23-001831-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017023001831/clsd-20230202.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-001831

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer